Barclays PLC reiterated their hold rating on shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) in a research report released on Friday morning. They currently have a $22.00 price target on the biopharmaceutical company’s stock.
Other research analysts have also issued research reports about the stock. ValuEngine lowered shares of PTC Therapeutics from a hold rating to a sell rating in a research note on Thursday, September 7th. Zacks Investment Research upgraded shares of PTC Therapeutics from a hold rating to a buy rating and set a $23.00 price target on the stock in a research note on Wednesday, August 30th. BidaskClub lowered shares of PTC Therapeutics from a strong-buy rating to a buy rating in a research note on Friday, August 4th. Citigroup Inc. restated a buy rating and set a $17.00 price target (down previously from $28.00) on shares of PTC Therapeutics in a research note on Thursday, July 20th. Finally, William Blair assumed coverage on shares of PTC Therapeutics in a research note on Wednesday, August 23rd. They set a market perform rating and a $17.00 price target on the stock. One analyst has rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of Hold and an average target price of $17.10.
Shares of PTC Therapeutics (PTCT) opened at 20.55 on Friday. The stock’s market capitalization is $848.80 million. The stock’s 50 day moving average is $19.64 and its 200 day moving average is $14.98. PTC Therapeutics has a 52 week low of $4.03 and a 52 week high of $22.00.
PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.89) by $0.45. The firm had revenue of $47.96 million for the quarter, compared to analyst estimates of $28.78 million. PTC Therapeutics had a negative net margin of 88.43% and a negative return on equity of 81.84%. The company’s revenue for the quarter was up 206.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.14) EPS. Analysts anticipate that PTC Therapeutics will post ($2.35) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Barclays PLC Reaffirms Hold Rating for PTC Therapeutics, Inc. (PTCT)” was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://sportsperspectives.com/2017/09/12/barclays-plc-reaffirms-hold-rating-for-ptc-therapeutics-inc-ptct.html.
Large investors have recently bought and sold shares of the stock. AXA acquired a new position in PTC Therapeutics in the 1st quarter valued at $103,000. Nisa Investment Advisors LLC acquired a new position in PTC Therapeutics in the 2nd quarter valued at $125,000. Public Employees Retirement System of Ohio acquired a new position in PTC Therapeutics in the 2nd quarter valued at $142,000. Janney Montgomery Scott LLC acquired a new position in PTC Therapeutics in the 1st quarter valued at $163,000. Finally, Virginia Retirement Systems ET AL acquired a new position in PTC Therapeutics in the 1st quarter valued at $187,000. Institutional investors and hedge funds own 81.36% of the company’s stock.
PTC Therapeutics Company Profile
PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.
Receive News & Ratings for PTC Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.